Journal Mobile Options
Table of Contents
Vol. 102, No. 3-4, 2006
Issue release date: February 2006
Nephron Clin Pract 2006;102:c128–c132

Clopidogrel Diminishes Hemodialysis Access Graft Thrombosis

Trimarchi H. · Young P. · Forrester M. · Schropp J. · Pereyra H. · Freixas E.
Department of Medicine,aNephrology Section, and bInternal Medicine Section, Hospital Británico, Buenos Aires, Argentina

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The most common complication of hemodialysis (HD) access graft is thrombosis. Clopidogrel, an inhibitor of platelet aggregation, was assessed to prevent this serious complication. Methods: A prospective study in which 24 patients on chronic HD whose vascular accesses were grafts were divided into two groups: group A (n = 12, 50%) consisted of patients who did not receive antithrombotic therapy after graft creation, and group B (n = 12, 50%) received clopidogrel 75 mg/day from 2 days after surgery onwards. Both groups were not different according to age, gender, cause of renal failure, hematocrit levels, platelet counts and Kt/V. All patients’ thrombotic episodes were followed up from the day of graft surgery until thrombosis was diagnosed. Finally, the patient survival difference between both groups was determined. Results: Eleven thrombotic episodes were diagnosed in group A while one event was reported in group B (p < 0.001). Graft access days of patency were significantly longer in group B compared to group A (380.8 ± 170 vs. 90.1 ± 57.2, p < 0.001). Time that elapsed from dialysis initiation to graft creation was not different (group A 18 ± 12 days, group B 20 ± 10 days). Days on HD were different between both groups (group A 208.9 ± 97.2 vs. group B 583.2 ± 287.0, p < 0.001) and all patients from group A (n = 12, 100%) and 2 patients from group B (16.7%) died (p = 0.001). Major bleeding events were not reported. Conclusions: Clopidogrel significantly decreased thrombotic graft episodes. Patients on clopidogrel had a prolonged vascular access patency, longer time on HD and better survival.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Windus DW: Permanent vascular access: a nephrologist’s view. Am J Kidney Dis 1993;21:457–471.
  2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523–535.
  3. Feldman HI, Held PJ, Hutchinson JT, et al: Hemodialysis vascular access morbidity in the United States. Kidney Int 1993;43:1091–1096.
  4. Schwab SJ: Vascular access for hemodialysis. Kidney Int 1999;55:2078–2090.
  5. Fan PY, Schwab SJ: Vascular access. Concepts for the 1990s. J Am Soc Nephrol 1992;3:1–11.
  6. Domoto DT, Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 1991;62:737–743.
  7. Sreedhara R, Himmelfarb J, Lazarus M, Hakim R: Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994;45:1477–1483.
  8. Kaufman JS, O’Connor TZ, Zhang JH, Cronin RE: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003;14:2313–2321.
  9. Best JM, Lennon R, Ting HH, et al: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. Am J Cardiol 2002;39:1113–1119.

    External Resources

  10. US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999.
  11. Goldsmith DJA, Covic A: Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 2001;60:2059–2078.
  12. Braun WE, Phillips DF, Vidt DG: Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc 1984;16:603–607.
  13. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.
  14. Deray G, Bagnis C, Brouard R, et al: Clopidogrel activities in patients with renal function impairment. Clin Drug Invest 1998;4:319–328.

    External Resources

  15. Boneau B, Destelle G, on behalf of the Study Group: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939–943.

    External Resources

  16. Kaufman JS, Fiore L, Hasbargen JA, O’Connor T, Perdriset G: A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis 2000;10:127–131.
  17. Galbraith S, Fan P, Collins D, et al: Hemodialysis fistula thromboses: a prospective evaluation of anatomic versus non-anatomic causes (abstract). J Am Soc Nephrol 1992;3:365.
  18. Young EW, Dykstra DM, Goodkin DA, et al: Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002;61:2266–2271.
  19. Munda R, First MR, Alexander JW, et al: Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983;249:219–222.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50